Potential Alzheimer’s Treatment Targeting Bacteria Seen as Safe in Early Trial, Cortexyme Says

Potential Alzheimer’s Treatment Targeting Bacteria Seen as Safe in Early Trial, Cortexyme Says
COR388, Cortexyme's investigational compound to treat Alzheimer’s, was safe and well-tolerated in healthy volunteers taking part in a Phase 1 clinical trial, the company announced. COR388 is a first-in-class bacterial protease inhibitor designed to target a specific bacteria that has been identified in both the brain tissue and cerebrospinal fluid of Alzheimer’s patients. Stephen Dominy, MD, Cortexyme’s co-founder and chief scientific officer, has discovered that Alzheimer’s symptoms and pathology are triggered by the presence of this particular pathogen, which has not been disclosed. Broad-spectrum antibiotics are unable to target this bacteria, and the use of CO
Subscribe or to access all post and page content.

One comment

  1. judy nichols says:

    Exciting news! Our mother battled this dreadful disease for ten years before passing. I was diagnosed with MCI at 66 last year
    and am very interested in the progress being made. I have already discussed with my neurologist my wishes should I be diagnosed
    with Alzheimer’s. My family, too, knows that I prefer to be a “guinea pig” to assist in finding a cure or ways to detect the disease as early as possible. I don’t want my children or anyone
    to have to go through this horrific disease! Thank you all for
    your contributions and publishing these updates!

Leave a Comment

Your email address will not be published. Required fields are marked *